When Merck and Schering-Plough revealed Monday that the active ingredient in their top-selling cholesterol meds Zetia and Vytorin had flunked a clinical trial measuring its effect on artery plaque, they opened themselves up to a barrage of attacks.

FORBES: Magazine Article

In a dismal earnings season for drug stocks, the biggest source of drama may be the diverging interests of Merck , which reported earnings Monday, and its partner Schering-Plough , which reports Wednesday.

FORBES: Merck And Schering's Uneasy Alliance